BRAF and central nervous system cancer: The role of BRAF alterations has been a topic of focused interest in pediatric glioma given the high prevalence of p.V600E (Class I) and BRAF-KIAA1549 fusions (Class II)6,7, with early evidence of success by BRAF-targeted therapy in this group8–10.